T1	total-participants 363 366	129
T2	ethinicity 367 374	Chinese
T3	ethinicity 419 428	Hong Kong
T4	eligibility 434 546	equired adjuvant tamoxifen for breast cancer after the completion of postoperative radiotherapy and chemotherapy
T5	intervention 20 64	levonorgestrel-releasing intrauterine system
T6	control 693 706	control group
T8	total-participants 1026 1028	94
T10	outcome 1106 1139	occurrence of submucosal fibroids
T13	outcome 1329 1355	de novo endometrial polyps
T14	outcome 1521 1550	breast cancer recurrence rate
T17	outcome 1591 1612	cancer-related deaths
T18	outcome 1178 1201	endometrial hyperplasia
T19	iv-bin-abs 1208 1209	0
T11	iv-bin-abs 1141 1142	1
T23	iv-bin-percent 1144 1148	1.8%
T12	cv-bin-abs 1164 1165	2
T24	cv-bin-percent 1167 1171	3.4%
T15	cv-bin-abs 1552 1554	10
T25	cv-bin-percent 1556 1561	17.2%
T16	iv-bin-abs 1577 1578	6
T26	iv-bin-percent 1580 1585	10.0%
T21	cv-bin-abs 1614 1615	6
T27	cv-bin-percent 1617 1622	10.3%
T22	iv-bin-abs 1638 1639	5
T28	iv-bin-percent 1641 1645	8.3%
